טוען...
A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
The efficacy of melphalan (MEL) 140 mg/m(2) pre-transplant conditioning versus MEL 200 mg/m(2) for the elderly is still debated. We hypothesized that single-agent intravenous busulfan (BU) would show significant anti-myeloma efficacy and be better tolerated by elderly patients. A prospective 3+3 dos...
שמור ב:
| הוצא לאור ב: | Cell Transplant |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6923548/ https://ncbi.nlm.nih.gov/pubmed/31619057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689719880541 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|